Compare Davita Inc (DVA) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Invesco Ltd. — how do they compare? Davita Inc trades at $178.63 (market cap $11.38B), while Invesco Ltd. trades at $31.46 (market cap $13.85B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.74% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | IVZ | |
|---|---|---|
Market Cap | $11.38B | $13.85B |
Sector | Health | Financials |
52-Week High | $240.96 | $32.01 |
52-Week Low | $103.87 | $20.67 |
Enterprise Value | $24.10B | $24.01B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Invesco (IVZ) trades at $31.74, near its 52-week high, with a bullish technical signal supported by moving averages. The company reported mixed quarterly earnings but maintains strong operating cash flow of $1.53 billion for 2025. Recent news highlights record assets under management and positive analyst coverage, though profitability metrics show net income margin at -0.93%.
The outlook remains cautiously optimistic with a consensus price target of $32.50, offering modest upside. Key risks include volatile earnings and expense pressures, while institutional interest and dividend payments provide support. Investors should weigh solid cash generation against margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
